REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K -November 30, 2023 at 01:09 pm EST

REPLICEL LIFE SCIENCES INC.


CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS





For the six months ended September 30, 2023 and 2022


...

Related Keywords

China ,Canada ,United States ,Vancouver ,British Columbia ,Taiwan ,Hong Kong ,Macau ,Chinese ,Canadian ,Lee Buckler ,David Hall ,Replicel Life Sciences Inc ,Company Stock Option Plan ,Company Or Replicel ,International Financial Reporting Standards ,Shiseido Company ,Company Options ,Venture Exchange ,Party Transactions ,Bus Partnership ,Trichoscience Innovations Inc ,International Accounting Standards Board ,Mainpointe Pharmaceuticals ,Technology Transfer Agreement ,China Health Industry Co ,While The Company ,National Instrument ,Given The Company ,Canadian Dollars ,Interim Financial ,Consolidated Interim Statements ,Cel Life Sciences ,Ontario Business Corporations Act ,Replicel Life Sciences ,Trichoscience Innovations ,Accounting Estimates ,Collaboration Agreement ,Health Industry ,Replicel Injector Product Line ,Interpretations Effective ,Collaborative Agreement ,Greater China ,Mainland China ,Contract Liability ,License Fee ,Share Purchase Agreement ,Distribution Agreement ,Cel Injector Product ,Royalty Participation Agreement ,Chief Technology Officer ,Discounted Market Price ,Aging Skin ,Chronic Tendinosis ,Treatment Androgenic Alopecia ,Replicel Injector Product ,Payback Period ,Issue Date ,Required Redemption Date ,Redemption Price ,Novel Coronavirus ,Canada Emergency Business Account ,Government Grants ,Government Assistance ,Government Grant ,News Release ,Preferred Shares ,Each Warrant ,Stock Option Plans ,Stock Option Plan ,Risk Management ,Shiseido Company Limited ,Markets ,